Antibody Drug articles & resources on Made-in-China.com

MHLW Has Approved Takeda Pharmaceutical's NDA of Adcetris 50mg Intended to Treat Patients

Jan 21, 2014

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Takeda Pharmaceutical's new drug application (NDA) of Adcetris (brentuximab vedotin) 50mg intended to treat patients with CD30 positive relapsed or refractory hodgkin ...

Tags: Drug Adcetris, antibody-drug conjugate

Seattle Genetics Has Received Approval of ADCETRIS

Jan 18, 2014

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare ...

Tags: Health, Medicine

A New Combination of Drugs Might Prolong Life in Certain Older Leukemia Patients

Jan 10, 2014

A new combination of drugs might prolong life in certain older leukemia patients, a new study suggests. The research, led by German scientists, included nearly 800 older people (average age 73) who had been diagnosed with chronic ...

Tags: Drug, Drug Combo, Leukemia

Sutro Biopharma Has Entered Into a Collaboration Agreement

Jan 8, 2014

Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration ...

Tags: Bispecific Antibodies, Sutro's Cell-Free Protein Synthesis Technology

AnaptysBio Has Commenced an Antibody Development Program with Momenta Pharmaceuticals

Dec 20, 2013

US-based privately-held therapeutic antibody firm AnaptysBio has commenced an antibody development program with Momenta Pharmaceuticals, focused on the development of new antibodies against a therapeutically relevant target. Both the ...

Tags: Anaptysbio, Antibody Development Deal

Sutro Biopharma Has Received $26m in a Series D Financing

Dec 13, 2013

Sutro Biopharma has received $26m in a Series D financing, which will be used for the expansion of its proprietary immuno-oncology product pipeline. The company is currently using its cell-free protein synthesis technology to develop new ...

Tags: Health, Medicine

Covagen Announced It Has Secured CHF42m in a Tranched Series B Financing

Dec 11, 2013

Covagen has announced that the company has secured CHF42m in a tranched Series B financing with an option to obtain an additional CHF14m that would increase the total amount of the financing round to CHF56m. This financing will mainly ...

Tags: Covagen, Medicine

Roche and Molecular Partners Have Entered Into a Research Collaboration

Dec 9, 2013

Roche and Molecular Partners have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular' DARPin biologics conjugated to toxic agents ...

Tags: Roche, Molecular Partners

SCT and ABB Have Entered Into a Collaboration to Identify New Therapeutic Antibodies

Nov 22, 2013

Single Cell Technology (SCT) and AB Biosciences (ABB) have entered into a collaboration to identify new therapeutic antibodies. Under the deal, SCT will use its patented platform to screen plasma cells, measure the kinetics of secreted ...

Tags: Health, Medicine

Sorrento Therapeutics Announced a Definitive Agreement to Acquire Concortis Biosystems

Nov 18, 2013

Sorrento Therapeutics, a clinical-stage biopharmaceutical company, has announced a definitive agreement to acquire US-based Concortis Biosystems. This acquisition provides Sorrento Therapeutics with a comprehensive technology platform for ...

Tags: Concortis Biosystems, Sorrento Therapeutics

The Patent Application Covers Synta's Proprietary HDC Technology

Nov 4, 2013

Synta Pharmaceuticals has announced the publication of the company's first patent application covering its proprietary Hsp90-inhibitor drug conjugate (HDC) platform, which leverages the company's expertise in chaperone biology and medicinal ...

Tags: Health, Medicine

AstraZeneca's Global Biologics Research Division Medimmune Will Acquire Spirogen

Oct 18, 2013

AstraZeneca's global biologics research and development division MedImmune will acquire Spirogen, a biotech firm focused on antibody-drug conjugate technology for use in oncology. Spirogen's complete shares will be purchased by MedImmune ...

Tags: biologics research, AstraZeneca

BioInvent and Bayer Pharma Have Extended Their Collaboration to Develop Antibodies

Oct 16, 2013

BioInvent International and Bayer Pharma have extended their collaboration to develop antibodies from BioInvent's n-CoDeR libraries. As part of the deal, which is an extension of the 2008 license agreement, Bayer will broaden its access ...

Tags: Bioinvent, Bayer

Develops Novel Anticancer Therapeutics Has Signed a Licensing Agreement with Novartis

Oct 15, 2013

US-based biotechnology firm that develops novel anticancer therapeutics using antibody-drug conjugate (ADC) technology, ImmunoGen (IMGN) has signed a licensing agreement with Novartis, pursuant to which, Novartis has the exclusive right to ...

Tags: Immunogen, Novartis, ADC Technology

AnaptysBio Has Expanded Its Proprietary Immunotherapy Antibody Portfolio

Sep 3, 2013

Therapeutic antibodies developer AnaptysBio has expanded its proprietary immunotherapy antibody portfolio to add multiple new combination therapies. The company developed a proprietary anti-PD-1 antibody, called ANB011, with key ...

Tags: AnaptysBio, Antibody Portfolio

Antibody Drug

Related Products